ClinicalTrials.gg
CompletedNCT05927532Updated Mar 17, 2026

Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study

An interventional study of Argyle Safety Fistula Cannula with Anti-Reflux Valve in End Stage Renal Failure on Dialysis, sponsored by Mozarc Medical US LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Mozarc Medical US LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
350th of 638
40 · median 48
Started
2024
with 23 others
No phase
287 of 765
28 open now
Registered
686th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 350th largest by enrollment of the 638 interventional ones that give a count, is one of 24 that started in 2024, is one of 287 with no phase, and was the 686th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.

Read the detailed description

The study will be performed at up to 5 US hemodialysis clinics.

Qualified patients who choose to participate and sign informed consent will be enrolled in the study. The investigational sites chosen to participate in this study will be trained on the insertion procedure using plastic fistula cannulas according to established curriculum. A combination of didactic training followed by insertion using a cannulation arm will be conducted. Cannulation on consented subjects will begin after the inserter demonstrates proficiency on the cannulation arm. Proficiency definitions are outlined in the protocol. After two supervised (by Medtronic and/or dedicated, trained super user) successful cannulations on consented subjects, the clinician will be permitted to cannulate without supervision.

Data supporting the primary, secondary, and exploratory objectives will be captured following thirty-six (36) hemodialysis sessions for each enrolled subject.

Cannulations will be performed by a minimum of five different clinicians at up to 5 dialysis clinic sites.

The investigational sites chosen to participate in this study will be trained on the insertion procedure using plastic fistula cannulas for a pre-determined period and according to established curriculum. A combination of didactic training followed by insertion using a cannulation arm will be conducted. After two supervised (by Medtronic and/or dedicated, trained super user) successful cannulations on consented subjects, the clinician will be permitted to cannulate without supervision and the data collection for the primary and secondary objectives will begin. Hemodialysis sessions will be performed, according to the investigator's prescription, throughout the duration of the study. Dialysis adequacy will be verified at baseline and during the mid-week session on weeks 1, 3, 6 and 12. Other than the blood sampling, there are no study-specific procedures, other than cannulation with the Argyle™ Safety Fistula Cannula with Anti-Reflux Valve, that will be required.

03

Conditions studied

  • End Stage Renal Failure on Dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who is aged 18 years or older who signed
  • Subject is undergoing in-center hemodialysis
  • Subject has an arteriovenous fistulae (AVF) fistula that was determined to be mature by standard clinical definition

Exclusion criteria

Exclusion Criteria:

  • Subject is enrolled in another study that could confound the results of this study, without documented pre-approval
  • Subject with an existing arteriovenous graft
  • Subjects with known allergies to plastics
  • Subjects who are unable to read or respond to the questionnaire about satisfaction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Argyle Fistula Cannula Subjects

    All subjects enrolled in the study and treated with the Argyle Safety Fistula Cannula with Anti-reflux Valve

    Device: Argyle Safety Fistula Cannula with Anti-Reflux Valve

Interventions

  • DeviceArgyle Safety Fistula Cannula with Anti-Reflux Valve

    The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula

06

What researchers measure

Primary outcomes

  1. Successful Hemodialysis Sessions

    The primary objective is the percentage of successful hemodialysis sessions using the Argyle™ Safety Fistula Cannula with Anti-reflux Valve.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Successful Cannulations

    Report the percentage of successful cannulations to achieve successful cannulation in each subject

    Time frame: through study completion, an average of 1 year

  2. Cannulation Locations with securement details

    Characterize cannulation locations and details on the securement of the cannulas after taping during the hemodialysis session by evaluating the staff-reported insertion sites captured on the Dialysis Session case report form

    Time frame: through study completion, an average of 1 year

  3. Access-related complications requiring procedural intervention

    Quantify the number of subjects who had a procedure to correct access-related complications

    Time frame: through study completion, an average of 1 year

  4. Compare prescribed blood flow rates

    Compare prescribed blood flow rates with plastic fistula cannula to average blood flow achieved

    Time frame: through study completion, an average of 1 year

  5. Dialysis adequacy

    Compare baseline dialysis adequacy (e.g., spKt/V and urea reduction ratio (URR) to measure collected at 1, 3, 6 and 12 weeks). The average spKt/V and URR will be compared to measurements reported at basline using steel needles. A repeated measures approach will be utilized to compare baseline to follow-up dialysis adequacy measurements.

    Time frame: through study completion, an average of 1 year

  6. Cannulator Satisfaction Questionnaire

    Assess inserter satisfaction (survey), i.e., ability to access deep fistulas, insertion locations, securement technique, ability to determine proper placement without the usual pulsing flashback seen with traditional needles. Mean satisfaction score (and associated 95% confidence intervals) prior to first use and following final cannulation will be reported.

    Time frame: through study completion, an average of 1 year

  7. Subject Satisfaction Questionnaire

    Characterize subject satisfaction using standardized survey to assess insertion pain

    Time frame: through study completion, an average of 1 year

  8. Impact of delay between training and use of device

    Evaluate any impact of delay between training and use of the subject devices, or time elapsed between cases for each clinician and successful and unsuccessful cannulations. The proportion of successful and unsuccessful cannulations will be predicted with clinician and time between training and cannulation attempt using logistic regression. Statistical significance of the covariate "time between training and cannulation attempt" will be reported.

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. Summary of Needle Stick Injury within past 6 months from start of study by investigational site

    Summarize any reported needle stick injury reports in the past 6 months from the start of the study, as permitted by the investigational site

    Time frame: in the past 6 months from the start of the study

  2. Time to successful cannulation

    Report the time required to achieve successful cannulation

    Time frame: During procedure

07

Study locations

3 sites
  • DaVita Hartford
    Hartford, Connecticut 06082, United States
  • DaVita Columbus
    Columbus, Georgia 31904, United States
  • DaVita Norfolk
    Norfolk, Virginia 23505, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Dec 2024, 9 months.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 9 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2023
First posted
Jul 3, 2023
StartActual
Mar 10, 2024
Primary completionActual
Dec 15, 2024
CompletionActual
Dec 15, 2024
Results delay requested
Nov 4, 2025
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05927532
Lead sponsor
Mozarc Medical US LLC
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Mar 10, 2024
Primary completion
Dec 15, 2024
Completion
Dec 15, 2024
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion